歌礼制药-B宣布,其用于治疗斑块状银屑病的候选药物ASC50——一款同类首创且具备同类最佳潜力的口服小分子IL-17A抑制剂——在美国开展的28天概念验证临床研究中取得积极结果。
歌礼制药-B宣布,其用于治疗斑块状银屑病的候选药物ASC50——一款同类首创且具备同类最佳潜力的口服小分子IL-17A抑制剂——在美国开展的28天概念验证临床研究中取得积极结果。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.